ECSP045202A - Procedimiento para la fabricacion de compuestos organicos - Google Patents

Procedimiento para la fabricacion de compuestos organicos

Info

Publication number
ECSP045202A
ECSP045202A EC2004005202A ECSP045202A ECSP045202A EC SP045202 A ECSP045202 A EC SP045202A EC 2004005202 A EC2004005202 A EC 2004005202A EC SP045202 A ECSP045202 A EC SP045202A EC SP045202 A ECSP045202 A EC SP045202A
Authority
EC
Ecuador
Prior art keywords
procedure
manufacture
organic compounds
ketoester
hydroxy
Prior art date
Application number
EC2004005202A
Other languages
English (en)
Inventor
Prasad Koteswara Kapa
Guang-Pei Chen
Eric M Loeser
Ulrich Beutler
Werner Zaugg
Michael J Girgis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045202A publication Critical patent/ECSP045202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se describe un método para preparar una sal de metal alcalino que comprende: (a) condensar un disililoxidieno con un aldehído en presencia de un catalizador de titano (IV) en un solvente inerte para formar 5(S)-hidroxi-3-cetoéster; (b) reducir el 5(S)-hidroxi-3-cetoéster a un 3(R),5(S)-dihidroxiéster en presencia de un di(alquilo inferior)metoxiborano; y (c) hidrolizar el 3(R),5(S)-dihidroxiéster en presencia de una base acuosa para formar una sal de metal alcalino.
EC2004005202A 2002-01-28 2004-07-22 Procedimiento para la fabricacion de compuestos organicos ECSP045202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35231602P 2002-01-28 2002-01-28
US38318802P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
ECSP045202A true ECSP045202A (es) 2004-09-28

Family

ID=27669055

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005202A ECSP045202A (es) 2002-01-28 2004-07-22 Procedimiento para la fabricacion de compuestos organicos

Country Status (19)

Country Link
US (3) US6835838B2 (es)
EP (1) EP1472227B1 (es)
JP (1) JP2005516064A (es)
KR (2) KR20100091267A (es)
CN (2) CN100378081C (es)
AU (4) AU2003239294B2 (es)
BR (1) BR0307236A (es)
CA (1) CA2472340A1 (es)
CO (1) CO5601045A2 (es)
EC (1) ECSP045202A (es)
IL (1) IL162817A0 (es)
MX (1) MXPA04007308A (es)
NO (1) NO327363B1 (es)
NZ (3) NZ534136A (es)
PL (1) PL371383A1 (es)
RU (1) RU2360903C2 (es)
SG (2) SG161742A1 (es)
WO (1) WO2003064382A2 (es)
ZA (1) ZA200405239B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100349877C (zh) 2001-07-13 2007-11-21 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
DK1466905T3 (da) * 2001-11-14 2011-08-22 Nissan Chemical Ind Ltd Fremgangsmåde til fremstilling af en optisk aktiv oxoheptensyreester
AU2003226971B2 (en) * 2002-01-31 2006-11-30 Novartis Ag Process for the manufacture of HMG-CoA reductase inhibitors
US7339062B2 (en) * 2002-09-20 2008-03-04 Nissan Chemical Industries, Ltd. Method for producing a 3,5-dihydroxy-6-heptenoate
CN101219992B (zh) * 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN1763015B (zh) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
US8487105B2 (en) * 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
RU2425034C1 (ru) * 2010-01-11 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения производных (e)-4-(6,7-диметокси-2-метил-3-хинолил)-3-бутен-2-она
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
WO2012025939A1 (en) * 2010-08-25 2012-03-01 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP2638013A4 (en) * 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
WO2012140490A2 (en) 2011-04-11 2012-10-18 Aurobindo Pharma Limited Process for preparing quinoline derivative
CN103755568B (zh) * 2013-12-10 2015-10-28 江西科技师范大学 IeodomycinA和B立体选择性合成方法
US10676441B2 (en) 2015-08-05 2020-06-09 Api Corporation Method for producing pitavastatin calcium
CN108976168B (zh) * 2017-06-02 2020-09-25 浙江京新药业股份有限公司 一种匹伐他汀半钙盐晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JP3554036B2 (ja) * 1994-09-06 2004-08-11 宇部興産株式会社 光学活性な７−置換キノリル−３，５−ジヒドロキシ−ヘプト−６−エン酸エステル誘導体の製造方法
DK1466905T3 (da) * 2001-11-14 2011-08-22 Nissan Chemical Ind Ltd Fremgangsmåde til fremstilling af en optisk aktiv oxoheptensyreester
US8212035B2 (en) * 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention

Also Published As

Publication number Publication date
SG157225A1 (en) 2009-12-29
US20040249154A1 (en) 2004-12-09
IL162817A0 (en) 2005-11-20
AU2006225205B2 (en) 2009-08-06
WO2003064382A2 (en) 2003-08-07
BR0307236A (pt) 2004-12-07
ZA200405239B (en) 2005-07-27
EP1472227B1 (en) 2016-04-27
AU2006225206A1 (en) 2006-10-26
AU2006225205A1 (en) 2006-10-26
CO5601045A2 (es) 2006-01-31
AU2003239294B2 (en) 2006-10-19
RU2360903C2 (ru) 2009-07-10
CA2472340A1 (en) 2003-08-07
NO327363B1 (no) 2009-06-15
CN100378081C (zh) 2008-04-02
SG161742A1 (en) 2010-06-29
KR20040077883A (ko) 2004-09-07
JP2005516064A (ja) 2005-06-02
NZ554367A (en) 2008-11-28
CN1660818A (zh) 2005-08-31
CN1625550A (zh) 2005-06-08
WO2003064382A3 (en) 2003-12-11
US20090299065A1 (en) 2009-12-03
KR20100091267A (ko) 2010-08-18
EP1472227A2 (en) 2004-11-03
NZ534136A (en) 2007-08-31
US20030208072A1 (en) 2003-11-06
NZ554366A (en) 2008-11-28
PL371383A1 (en) 2005-06-13
NO20043586L (no) 2004-10-07
AU2006225206B2 (en) 2009-08-06
RU2004126448A (ru) 2005-06-27
US6835838B2 (en) 2004-12-28
AU2009208129A1 (en) 2009-09-03
MXPA04007308A (es) 2004-10-29
US7572917B2 (en) 2009-08-11

Similar Documents

Publication Publication Date Title
ECSP045202A (es) Procedimiento para la fabricacion de compuestos organicos
GT199800113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
EA200200481A1 (ru) Способ получения производных 4-трифторметилсульфинилпиразола
ES2149734T1 (es) Metodo para la preparacion de citalopram.
TW200716582A (en) Process for making a pharmaceutical compound
EA200200900A1 (ru) Способ получения циталопрама
AR079399A2 (es) Procedimientos para preparar bifenazato
AR072075A2 (es) Un metodo para producir un lente antimicrobiano que comprende una sal metalica
AR055975A1 (es) Procedimiento para producir atorvastatina,sus sales farmaceuticamente aceptables y sus productos intermedios
EA200400252A1 (ru) Стабильная полиморфная модификация флибансерина, способ её промышленного получения и её применение для получения лекарственных средств
AR079237A2 (es) Proceso para la preparacion de derivados de dibenzo(b,f) azepina
BRPI0506690A (pt) processo para a preparação de 1,3-butileno glicol
AR018802A1 (es) Procedimiento de preparacion de un oxirano
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
PE20040991A1 (es) Separacion de intermediarios para la preparacion de escitalopram
AR043505A1 (es) Preparacion de beta-cetoamidas e intermediarios de reaccion
DE60224098D1 (de) Herstellung eines neolignans mittels durch ddq vermittelte dimerisierung von dihydroasaron
ITMI20032463A1 (it) Soluzione acquosa concentrata a base di ambroxolo
EA200401090A1 (ru) Композиция на основе диклофенака для местного лечения заболеваний орофарингеальной полости
BRPI0416274A (pt) método para produzir solução de amÈnio de ácido orgánico
BR0209657A (pt) Processo para a preparação de ésteres de ácidos carboxìlicos substituìdos por hidrólise enzimática
BRPI0407448A (pt) Processo quìmico
AR029767A1 (es) Procedimiento para la preparacion de compuestos de pirazolo (4, 3-d) pirimidin-7-onas-3-piridilsulfonilo y compuestos intermediarios utiles en dicho procedimiento.
AR030258A1 (es) Proceso para la preparacion de derivados de tiazol y compuestos relacionados
DK1670743T3 (da) Fremgangsmåde til fremstilling af optisk rene 2-(4-hydroxyphenoxy)propansyre-forbindelser